3 Clinical Trial Rebound Trends – And How to Scale Smoothly

The start of 2026 has seen a major shift in the clinical trial market. After three straight years of decline, 12-month starts are finally trending upward. Phase I-III trial starts increased by around 13% year-on-year in Q1. [1]

This is not a blip. Sponsor conviction is improving. Fewer clinical trials are being abandoned after announcement. Start-up times for clinical trials are being reduced, with funding incentives introduced to further streamline the process. [2,3] So far in 2026, biotechs have raised a median of $287.5 million, more than double that seen in Q1 2025 and the highest of any quarter since 2021. [4] With funding historically leading trial starts by around half, all the signs point to a significant rebound.

The market is giving clinical development teams a tailwind they have not had since 2021. The question is whether sponsors of all sizes implement the oversight infrastructure needed to keep pace with it. In this blog we explore the trends emerging – and how sponsors and CROs can ensure they scale smoothly as demand increases.

Acceleration is Fastest in Phase II

Phase II starts are increasing the fastest of all clinical phases. [1] That is where emerging sponsors often make their first serious investment in data oversight and quality infrastructure. However, adoption of risk-based quality management (RBQM) has historically been lower among smaller companies. [5]

Sponsors and CROs looking to scale effectively during this rebound period should remember RBQM is not just for 200-site global programs. A biotech running a 15-site Phase IIb study has less margin for error, not more. Just one problematic site can compromise the entire dataset. ICH E6(R3) certainly does not give smaller sponsors a pass, emphasizing the need for careful evaluation of the critical-to-quality (CtQ) factors involved in each trial and the risks associated with them. [6]

With earlier pressure on how trials are run, sponsors of all sizes must ensure they have robust oversight in place. Systematic risk-based oversight matters at every scale. 

Trials are Running Leaner

The number of active clinical trial sites is down nearly 8% from peak. [1] This can be attributed to several factors. Sponsors are getting smarter about site selection, using historical performance data to concentrate on fewer, higher-enrolling sites rather than casting a wide net. Decentralized trial elements, including eConsent, remote monitoring and eCOA, are also reducing the need for physical locations. When you combine that with cost pressures and the regulatory push toward risk-based oversight, the incentive structure now favors running leaner and investing in better data infrastructure over simply adding more sites.

While this shift can create efficiencies, it also makes it harder to maintain on-the-ground visibility. This makes data-driven, centralized oversight more important than ever. With sites likely to be spread over wider geographical areas, sponsors need to adopt adaptive monitoring which improves their ability to evaluate the performance of clinical trial sites and adjust site visitation plans more effectively and efficiently. The use of centralized oversight can also lead to further efficiencies. For example, consolidating disparate data sources into a single, summarized view can empower research teams to swiftly pinpoint anomalies and take action to mitigate risks, avoiding potentially costly issues.

The Safety Data Challenge is Growing

More trial starts means more safety data. But medical monitors are already overstretched, particularly those working at smaller sponsors and covering multiple studies simultaneously. At the same time, inappropriate and ad hoc tools can delay action and lack traceability while only providing generic analytics which fail to reflect how monitors actually work.

To deliver Medical & Safety Review (MSR) at scale, sponsors and CROs must explore how to accelerate time to insight and ensure audit-ready standardization as data volumes increase. Connecting clinical data and medical review signals with prioritized action and traceable follow-up allows medical monitors to detect issues earlier and demonstrate audit-ready compliance with confidence. Proven reuse models can also reduce burden on data management teams, delivering efficiency and scalability across study portfolios.

This is not just about keeping up with an increase in safety data but enhancing MSR to reduce patient exposure through earlier detection and action. The companies investing in systematic medical and safety review now will be better positioned than those scrambling to scale later.

Scaling Smoothly as Start Ups Increase

There has never been a better time to do more with less, whether that is time, resources or technology. The organizations that unlock meaningful efficiencies will be the ones willing to adapt how they work, not just add new tools on top of old processes.

Through every phase of this cycle of clinical trial growth and decline – the COVID surge, the three-year correction and now this recovery – the pattern has been the same. The teams that embed risk-based, data-driven oversight early are the ones that scale smoothly when volume picks up. The ones that wait end up scrambling. 

References

1. CluePoints analysis of ClinicalTrials.gov data, Q1 2026.
2. https://www.gov.uk/government/news/uk-clinical-trial-approval-times-twice-as-fast-with-ai-and-reforms
3. https://www.nihr.ac.uk/support-and-services/support-for-delivering-research/support-150-day-study-set-clinical-trials
4. https://www.biopharmadive.com/news/biotech-ipo-performance-q1-2026/815879/
5. https://link.springer.com/article/10.1007/s43441-025-00746-6
6. https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf

With over twenty-five years of international commercial experience in life sciences, healthcare, and telecommunications, Patrick has led global sales, product, marketing, professional services, and technical teams. He has also consulted on corporate and commercial strategy for various life sciences companies. During his ten-year tenure at ClinPhone, Patrick successfully positioned the company as the leading Clinical Technology Organization. Patrick co-founded CluePoints in 2012 and continues to serve as CCO.